Cytokinetics (CYTK) Stock Forecast & Price Target

Compare

1,134 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CYTK Analyst Ratings

Strong Buy

14 Buy

3 Hold

0 Sell

Based on 17 analysts giving stock ratings to

Cytokinetics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CYTK Stock 12 Month Forecast

Average Price Target

$78.15

▲(51.75% Upside)

Based on 17 Wall Street analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $78.15 with a high forecast of $120.00 and a low forecast of $41.00. The average price target represents a 51.75% change from the last price of $51.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"$30","121":"$121","52.75":"$52.8","75.5":"$75.5","98.25":"$98.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":78.15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$78.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$41.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,52.75,75.5,98.25,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.62,55.03384615384615,60.44769230769231,65.86153846153846,71.27538461538461,76.68923076923076,82.10307692307691,87.51692307692306,92.93076923076922,98.34461538461537,103.75846153846152,109.17230769230768,114.58615384615385,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.62,51.81461538461538,54.00923076923077,56.20384615384615,58.39846153846154,60.59307692307692,62.78769230769231,64.9823076923077,67.17692307692307,69.37153846153846,71.56615384615385,73.76076923076923,75.95538461538462,{"y":78.15,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.62,48.956923076923076,48.293846153846154,47.63076923076923,46.9676923076923,46.30461538461538,45.64153846153846,44.97846153846154,44.315384615384616,43.652307692307694,42.98923076923077,42.326153846153844,41.66307692307692,{"y":41,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":57.08,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.82,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.63,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.04,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.92,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.21,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.64,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.62,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$120.00

Average Price Target$78.15

Lowest Price Target$41.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Leonid Timashev

RBC Capital

$80→$82

Buy

59.22%

Upside

Reiterated

09/08/25

RBC Capital Remains a Buy on Cytokinetics (CYTK)

Jason Zemansky

Bank of America Securities

$45→$52

Hold

0.97%

Upside

Reiterated

09/04/25

Cytokinetics (CYTK) Gets a Hold from Bank of America Securities

Cory Kasimov

Evercore ISI

$60→$80

Buy

55.34%

Upside

Reiterated

09/03/25

Evercore ISI Sticks to Their Buy Rating for Cytokinetics (CYTK)

David Lebowitz

Citi

$77→$84

Buy

63.11%

Upside

Reiterated

09/03/25

Cytokinetics' Aficamten Poised to Transform Hypertrophic Cardiomyopathy Treatment Landscape Following Promising Phase 3 Results

Akash Tewari

Jefferies

$80

Buy

55.34%

Upside

Reiterated

09/03/25

Cytokinetics (CYTK) Gets a Buy from Jefferies

Serge Belanger

Needham

$72

Buy

39.81%

Upside

Reiterated

09/02/25

Buy Rating for Cytokinetics: Aficamten Shows Promising Results in Hypertrophic Cardiomyopathy Trials

Maxwell Skor

Morgan Stanley

$65

Buy

26.21%

Upside

Reiterated

09/02/25

Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK), United Therapeutics (NASDAQ: UTHR) and Voyager Therapeutics (NASDAQ: VYGR)

Gena Wang

Barclays

$53

Buy

2.91%

Upside

Reiterated

09/02/25

Barclays Sticks to Their Buy Rating for Cytokinetics (CYTK)

James Condulis

Stifel Nicolaus

$87→$96

Buy

86.41%

Upside

Reiterated

09/02/25

Cytokinetics Receives Buy Rating from James Condulis Amid Promising Developments and Strategic Partnerships

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

09/02/25

Cytokinetics (CYTK) Gets a Buy from Truist Financial

Roanna Ruiz

Leerink Partners

―

Buy

―

Reiterated

09/02/25

Buy Rating Justified for Cytokinetics Due to Aficamten's Advantages in HCM Treatment

Joseph Pantginis

H.C. Wainwright

$120

Buy

133.01%

Upside

Reiterated

09/02/25

Promising Phase 3 Trial Results Bolster Buy Rating for Cytokinetics' AficamtenValuation and potential impediments to achieving price target. We reiterate our Buy rating and $120 price target. Our price target is based on our clinical net present value (NPV) model. We believe this method is appropriate for capturing the value of the clinical stage pipeline by allowing us to flex multiple assumptions, including the chance of success, peak sales estimates, and year of commercial launch.

Tessa Romero

J.P. Morgan

―

Buy

―

Reiterated

09/01/25

J.P. Morgan Keeps Their Buy Rating on Cytokinetics (CYTK)

Ashwani Verma

UBS

$47→$41

Hold

-20.39%

Downside

Reiterated

09/01/25

Cytokinetics (CYTK) Receives a Hold from UBS

Salim Syed

Mizuho Securities

$84

Buy

63.11%

Upside

Reiterated

08/15/25

Cytokinetics (CYTK) Gets a Buy from Mizuho Securities

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Leonid Timashev

RBC Capital

$80→$82

Buy

59.22%

Upside

Reiterated

09/08/25

RBC Capital Remains a Buy on Cytokinetics (CYTK)

Jason Zemansky

Bank of America Securities

$45→$52

Hold

0.97%

Upside

Reiterated

09/04/25

Cytokinetics (CYTK) Gets a Hold from Bank of America Securities

Cory Kasimov

Evercore ISI

$60→$80

Buy

55.34%

Upside

Reiterated

09/03/25

Evercore ISI Sticks to Their Buy Rating for Cytokinetics (CYTK)

David Lebowitz

Citi

$77→$84

Buy

63.11%

Upside

Reiterated

09/03/25

Cytokinetics' Aficamten Poised to Transform Hypertrophic Cardiomyopathy Treatment Landscape Following Promising Phase 3 Results

Akash Tewari

Jefferies

$80

Buy

55.34%

Upside

Reiterated

09/03/25

Cytokinetics (CYTK) Gets a Buy from Jefferies

Serge Belanger

Needham

$72

Buy

39.81%

Upside

Reiterated

09/02/25

Buy Rating for Cytokinetics: Aficamten Shows Promising Results in Hypertrophic Cardiomyopathy Trials

Maxwell Skor

Morgan Stanley

$65

Buy

26.21%

Upside

Reiterated

09/02/25

Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK), United Therapeutics (NASDAQ: UTHR) and Voyager Therapeutics (NASDAQ: VYGR)

Gena Wang

Barclays

$53

Buy

2.91%

Upside

Reiterated

09/02/25

Barclays Sticks to Their Buy Rating for Cytokinetics (CYTK)

James Condulis

Stifel Nicolaus

$87→$96

Buy

86.41%

Upside

Reiterated

09/02/25

Cytokinetics Receives Buy Rating from James Condulis Amid Promising Developments and Strategic Partnerships

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

09/02/25

Cytokinetics (CYTK) Gets a Buy from Truist Financial

Roanna Ruiz

Leerink Partners

―

Buy

―

Reiterated

09/02/25

Buy Rating Justified for Cytokinetics Due to Aficamten's Advantages in HCM Treatment

Joseph Pantginis

H.C. Wainwright

$120

Buy

133.01%

Upside

Reiterated

09/02/25

Tessa Romero

J.P. Morgan

―

Buy

―

Reiterated

09/01/25

J.P. Morgan Keeps Their Buy Rating on Cytokinetics (CYTK)

Ashwani Verma

UBS

$47→$41

Hold

-20.39%

Downside

Reiterated

09/01/25

Cytokinetics (CYTK) Receives a Hold from UBS

Salim Syed

Mizuho Securities

$84

Buy

63.11%

Upside

Reiterated

08/15/25

Cytokinetics (CYTK) Gets a Buy from Mizuho Securities

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cytokinetics

1 Month

xxx

Success Rate

13/18 ratings generated profit

Average Return

+16.03%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 72.22% of your transactions generating a profit, with an average return of +16.03% per trade.

3 Months

xxx

Success Rate

10/18 ratings generated profit

Average Return

+25.84%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +25.84% per trade.

1 Year

Salim SyedMizuho Securities

Success Rate

34/51 ratings generated profit

Average Return

+31.34%

reiterated a buy rating 27 days ago

Copying Salim Syed's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +31.34% per trade.

2 Years

xxx

Success Rate

35/51 ratings generated profit

Average Return

+33.60%

reiterated a xxx

rating 27 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 68.63% of your transactions generating a profit, with an average return of +33.60% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CYTK Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CYTK has received 25 Buy Ratings, 16 Hold Ratings, and 0 Sell Ratings. CYTK average Analyst price target in the past 3 months is 78.15.

Each month's total comprises the sum of three months' worth of ratings.

CYTK Financial Forecast

CYTK Earnings Forecast

Next quarter’s earnings estimate for CYTK is -$1.57 with a range of -$1.81 to -$1.29. The previous quarter’s EPS was -$1.12. CYTK beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.13% of the time in the same period. In the last calendar year CYTK has Outperformed its overall industry.

CYTK Sales Forecast

Next quarter’s sales forecast for CYTK is $6.05M with a range of $0.00 to $47.50M. The previous quarter’s sales results were $66.77M. CYTK beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.40% of the time in the same period. In the last calendar year CYTK has Outperformed its overall industry.

CYTK Stock Forecast FAQ

What is CYTK’s average 12-month price target, according to analysts?

Based on analyst ratings, Cytokinetics’s 12-month average price target is 78.15.

What is CYTK’s upside potential, based on the analysts’ average price target?

Cytokinetics has 51.75% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CYTK a Buy, Sell or Hold?

Cytokinetics has a consensus rating of Strong Buy which is based on 14 buy ratings, 3 hold ratings and 0 sell ratings.

What is Cytokinetics’s price target?

The average price target for Cytokinetics is 78.15. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $120.00 ,the lowest forecast is $41.00. The average price target represents 51.75% Increase from the current price of $51.5.

What do analysts say about Cytokinetics?

Cytokinetics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of CYTK?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Cytokinetics (CYTK) Stock Forecast & Price Target

CYTK Analyst Ratings

CYTK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cytokinetics

CYTK Analyst Recommendation Trends

CYTK Financial Forecast

CYTK Earnings Forecast

CYTK Sales Forecast

CYTK Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts